<DOC>
	<DOCNO>NCT01972763</DOCNO>
	<brief_summary>The purpose study determine effectiveness Ranibizumab 0.5 mg 1.0 mg subject previously treat Bevacizumab subsequently switch Aflibercept . These subject demonstrate sub-optimal therapeutic response previous therapy ; therefore , study aim see Ranibizumab may great treatment effect .</brief_summary>
	<brief_title>Ranibizumab Recalcitrant Wet Age-related Macular Degeneration Eyes Previously Switched From Bevacizumab and/or Ranibizumab Aflibercept .</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Ability provide write informed consent comply study assessment full duration study Age great equal 50 year Bestcorrected ETDRS VA 20/25 20/320 Total area subretinal hemorrhage and/or fibrosis comprise less 50 % lesion Any neovascular lesion type ARMD previously receive least 3 dos 1.25 mg bevacizumab and/or ranibizumab ( minimum 3 monthly injection ) follow 3 monthly dos aflibercept 2.0 mg ( last injection within 8 week ) evidence recalcitrant ARMD , define least one following : persistent subretinal fluid without intraretinal cystic edema SDOCT and/or leakage fluorescein angiography Pregnancy ( positive pregnancy test ) lactation premenopausal woman use adequate contraception . The following consider effective mean contraception : surgical sterilization use oral contraceptive , barrier contraception either condom diaphragm conjunction spermicidal gel , IUD , contraceptive hormone implant patch Any condition investigator believe would pose significant hazard subject investigational therapy initiate Participation another simultaneous medical investigation trial History prior vitrectomy surgery Previous treatment photodynamic therapy , radiation , intravitreal drug delivery , dexamethasone triamcinolone Subretinal hemorrhage involve central fovea &gt; 1 disc area , subfoveal atrophy CNVM secondary cause ARMD Previous retinal pigment epithelial tear</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>